Navigation Links
Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant
Date:12/15/2008

JEFFERSON, N.C., Dec. 15 /PRNewswire/ -- Inhalers used for delivering albuterol, a fast-acting bronchial dilator, currently use propellants such as ozone-depleting CFC's, which are banned by the FDA beginning December 31st, 2009, or replacement HFA's. Both propellants are also used as industrial refrigerants and eject the medicine, albuterol, at near-supersonic speeds.

The Next Safety device supplies medication in a stream of air by ejecting the medication from a microfluidic pump automatically as the patient breathes, solving three problems:

(1) Propellants are eliminated. Patients are no longer required to inhale refrigerants.

(2) The medicine is not ejected at high speeds, where it is deposited on the back of the throat and ingested. This is such a concern that certain manufacturers of the new HFA-based albuterol inhalers recommend that patients "rinse and spit" after each treatment.

(3) Patients do not need to time their inhalation to match the push of a button. This is particularly important when administering albuterol to children where the parent is pressing a button hoping the child will breath at the same time. Therefore, parents can never be certain of dosing, which is one reason why 25% of all emergency room visits in the US are related to asthma.

The other method used to dose albuterol is the nebulizer, a large compressor-driven device that essentially sprays droplets of albuterol while a child breathes from a mist for a 20 - 30 minute period. This treatment, invented in 1975, is cumbersome and often not available to an asthmatic when a fast-acting dose of albuterol is needed.

Phillip Weaver, the President of Next Safety and an inventor of the technology, explains: "The device uses a silicon microfluidic pump to eject droplets of an off-the-shelf FDA-approved solution of albuterol sulfate in water that are a predetermined size into an air stream created by a miniature blower to deliver the droplets at the same speed of the patient's inhalation and in the correct size range for bronchial delivery."

According to Dr. Tom Stearn, a pulmonologist and consultant for Next Safety, "The platform offers the ability to deliver not only albuterol in air, but also other medications for treating asthma, such as fluticasone propionate and salmeterol xinofoate, the components of Advair." Certain chemical patents for Advair expired in August 2008.

The device also provides an electronic output to PDA's so that, in the future, doctors can monitor the results of specific doses of medications in addition to patient compliance.

Advanced designs of the platform use measurements of exhaled nitric oxide (NO) together with peak respiratory flow, which when combined are a predictor of an asthma attack, to automatically adjust doses and provide alarms to physicians and parents.

    Photos:
   http://www.ereleases.com/pr/2008-NextSafety.jpg
   http://www.ereleases.com/pr/2008-NextSafety2.jpg


    Website:http://www.nextsafety.com

    Contact:

George Colvard, COO Next Safety, georgecolvard@nextsafety.com, 336-246-7700

Philip Weaver, President Next Safety, philipweaver@nextsafety.com, 336-246-7700

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Next Safety, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Planned safety analysis of a breast cancer prevention study reveals encouraging news for Exemestane
2. Controversial New Pool & Spa Safety Act Will Create Public Pool Closures Nationwide
3. Nursing Data on Patient Safety in California Will Expand to Include Two Pacific Northwest States
4. FDA Panel Mulls Safety of Asthma Meds
5. Quantros and ISMP Announce Collaboration Agreement to Further Medication Safety
6. Top Heart Programs Choose Safety of Medivances Non-Invasive Arctic Sun(R) for Therapeutic Hypothermia
7. Quantros Patient Safety Center Receives Certification as a Patient Safety Organization (PSO)
8. RF Technologies(R) Introduces Safe Place(R) Usage Program Financing for Its Infant Security, Pediatric Security and ED Safety Solutions
9. SafetyTies Keep Getting Safer: Newest Neckties Reduce the Spread of Germs and Stylishly Feature the Microbes They Fight
10. South Florida Dermatologists Win Over Golf Fans With Sun Safety Outreach at LPGA Playoffs
11. Talyst Moves Patient Safety and Inventory Control Beyond the Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 05, 2016 , ... The talus is the part ankle ... falls, or traffic accidents can cause the talus bone to be fractured, and a ... In a first-of-its-kind procedure using 3D printing technology, internationally renowned orthopedic surgeon Dr. ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... announces the Everlasting Glove, a sports invention that aids in the improvement of ... Manufacturing industry is worth $9 billion," says Scott Cooper, CEO and Creative Director ...
(Date:5/4/2016)... ... 2016 , ... Trinity Health today launched its inaugural Innovation ... at improving care and reducing readmission rates for patients who are dually eligible ... is to drive innovation that transforms our ministry and our industry to be ...
(Date:5/4/2016)... AZ (PRWEB) , ... May 04, 2016 , ... ... Annual Technology & Business Conference. The conference opened on Tuesday with Frank Luntz, ... discussion on NCPDP’s PDMP Solution provided a deep dive on NCPDP’s model solution ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Level 10 Head ... her verbal commitment to the University of Arizona for the fall of 2019. ... decision last month. Brovedani’s commitment to the GymCats came from her connection with the ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 According ... Size, Share, Development, Growth and Demand Forecast to 2022 ... Field Strength (High Field, Very High Field, Low to ... Head and Neck, Spine, Musculoskeletal, Vascular, Breast, Pelvic and ... magnetic resonance imaging (MRI) market was valued at $5,351.7 ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... today announced data from the first cohort of ... trial (the OVATION Study) combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  In the first three patients ...
Breaking Medicine Technology: